Studies have shown that inhibiting NLRP3 is a feasible strategy to reduce adverse cardiac remodeling and improve left ventricular function in patients with heart failure, and blocking the NLRP3 inflammatory pathway has potential benefits for patients with heart failure [56]. Here, NLRP3 is linked to heart failure.